The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK will gain complete global rights to the therapy. Chimagen will also receive up to $550m in success-based development and ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...

GSK is delivering consistent financial performance ... So with that, I'll now hand over to Luke and Deborah to talk you through our commercial performance. Thanks, Emma. Please turn to the ...

GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...